1

Obinutuzumab (GA101): A Comprehensive Overview

obinutuzumab388468
Obinutuzumab, referred to as GA101, represents a novel monoclonal antibody designed in treat lymphocytic leukemia. This drug targets this surface antigen present on B cells, inducing ADCC and apoptosis. Clinical https://www.targetmol.com/compound/obinutuzumab
Report this page

Comments

    HTML is allowed

Who Upvoted this Story